{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:54:33Z","timestamp":1772726073039,"version":"3.50.1"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>This Policy Statement was retired June 2012.<\/jats:title>\n               <jats:p>This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.<\/jats:p>","DOI":"10.1542\/peds.2009-0466","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T00:25:35Z","timestamp":1238459135000},"page":"1412-1420","source":"Crossref","is-referenced-by-count":102,"title":["Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine"],"prefix":"10.1542","volume":"123","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2009,5,1]]},"reference":[{"key":"2023092514213178700_R1","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics.\u20082007;119(1):171\u2013182","DOI":"10.1542\/peds.2006-3134"},{"key":"2023092514213178700_R2","doi-asserted-by":"crossref","unstructured":"Charles MD, Holman RC, Curns AT, Parashar UD, Glass RI, Bresee JS. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993\u20132002. Pediatr Infect Dis J.\u20082006;25(6):489\u2013493","DOI":"10.1097\/01.inf.0000215234.91997.21"},{"key":"2023092514213178700_R3","doi-asserted-by":"crossref","unstructured":"Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children &lt;5 years of age in the United States, 1993\u20132003. J Infect Dis.\u20082007;195(8):1117\u20131125","DOI":"10.1086\/512863"},{"key":"2023092514213178700_R4","doi-asserted-by":"crossref","unstructured":"Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis.\u20081996;174(suppl 1):S5\u2013S11","DOI":"10.1093\/infdis\/174.Supplement_1.S5"},{"key":"2023092514213178700_R5","doi-asserted-by":"crossref","unstructured":"Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics.\u20082007;119(4):684\u2013697","DOI":"10.1542\/peds.2006-2876"},{"key":"2023092514213178700_R6","doi-asserted-by":"crossref","unstructured":"Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics.\u20082007;119(1):11\u201318","DOI":"10.1542\/peds.2006-2058"},{"key":"2023092514213178700_R7","doi-asserted-by":"crossref","unstructured":"Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine.\u20082006;24(22):4821\u20134829","DOI":"10.1016\/j.vaccine.2006.03.025"},{"key":"2023092514213178700_R8","doi-asserted-by":"crossref","unstructured":"Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med.\u20082006;354(1):23\u201333","DOI":"10.1056\/NEJMoa052664"},{"key":"2023092514213178700_R9","doi-asserted-by":"crossref","unstructured":"Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J.\u20082005;24(6):481\u2013488","DOI":"10.1097\/01.inf.0000164763.55558.71"},{"key":"2023092514213178700_R10","doi-asserted-by":"crossref","unstructured":"Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis.\u20082005;192(suppl 1):S6\u2013S16","DOI":"10.1086\/431511"},{"key":"2023092514213178700_R11","unstructured":"Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med.\u20082006;354(1):11\u201322"},{"key":"2023092514213178700_R12","doi-asserted-by":"crossref","unstructured":"Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J.\u20082005;24(9):807\u2013816","DOI":"10.1097\/01.inf.0000178294.13954.a1"},{"key":"2023092514213178700_R13","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine.\u20082004;22(21\u201322):2836\u20132842","DOI":"10.1016\/j.vaccine.2004.01.044"},{"key":"2023092514213178700_R14","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet.\u20082007;370(9601):1757\u20131763","DOI":"10.1016\/S0140-6736(07)61744-9"},{"key":"2023092514213178700_R15","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J.\u20082004;23(10):937\u2013943","DOI":"10.1097\/01.inf.0000141722.10130.50"},{"key":"2023092514213178700_R16","doi-asserted-by":"crossref","unstructured":"Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland LR, Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics.\u20082008;122(5). Available at: www.pediatrics.org\/cgi\/content\/full\/122\/5\/e1062","DOI":"10.1542\/peds.2008-1059"},{"key":"2023092514213178700_R17","doi-asserted-by":"crossref","unstructured":"Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J.\u20082007;26(3):221\u2013227","DOI":"10.1097\/01.inf.0000254391.71103.e8"},{"key":"2023092514213178700_R18","doi-asserted-by":"crossref","unstructured":"Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis.\u20082007;11(suppl 2):S36\u2013S42","DOI":"10.1016\/S1201-9712(07)60020-4"},{"key":"2023092514213178700_R19","doi-asserted-by":"crossref","unstructured":"Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics.\u20082008;121(6):1206\u20131212","DOI":"10.1542\/peds.2007-3793"},{"key":"2023092514213178700_R20","doi-asserted-by":"crossref","unstructured":"Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine.\u20082008;26(46):5798\u20135801","DOI":"10.1016\/j.vaccine.2008.08.030"},{"key":"2023092514213178700_R21","unstructured":"Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007\u2013May 2008. MMWR Morb Mortal Wkly Rep.\u20082008;57(25):697\u2013700"},{"key":"2023092514213178700_R22","doi-asserted-by":"crossref","unstructured":"Goveia MG, DiNubile MJ, Dallas MJ, Heaton PM, Kuter BJ. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J.\u20082008;27(7):656\u2013658","DOI":"10.1097\/INF.0b013e318168d29e"},{"key":"2023092514213178700_R23","doi-asserted-by":"crossref","unstructured":"Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J.\u20082007;26(12):1099\u20131104","DOI":"10.1097\/INF.0b013e31814521cb"},{"key":"2023092514213178700_R24","unstructured":"Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082009;58(RR-2):1\u201325"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/5\/1412\/1531442\/zpe00509001412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/5\/1412\/1531442\/zpe00509001412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:21:49Z","timestamp":1695651709000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/5\/1412\/71435\/Prevention-of-Rotavirus-Disease-Updated-Guidelines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,1]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-0466","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,1]]}}}